ABIVAX Société Anonyme (NASDAQ:ABVX) Receives Equal Weight Rating from Morgan Stanley

Morgan Stanley reaffirmed their equal weight rating on shares of ABIVAX Société Anonyme (NASDAQ:ABVX) in a research note published on Thursday, Marketbeat.com reports. The firm currently has a $12.00 price target on the stock.

Other equities analysts have also recently issued research reports about the company. JMP Securities reiterated a “market outperform” rating and set a $33.00 target price on shares of ABIVAX Société Anonyme in a research report on Friday, January 10th. Citizens Jmp upgraded ABIVAX Société Anonyme to a “strong-buy” rating in a research report on Wednesday, December 4th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $38.00.

ABIVAX Société Anonyme Trading Up 3.2 %

Shares of ABIVAX Société Anonyme stock opened at $7.06 on Thursday. ABIVAX Société Anonyme has a 52-week low of $5.50 and a 52-week high of $16.63. The company’s 50-day simple moving average is $6.71 and its 200-day simple moving average is $8.59.

Hedge Funds Weigh In On ABIVAX Société Anonyme

Several hedge funds and other institutional investors have recently bought and sold shares of the company. GAMMA Investing LLC acquired a new stake in ABIVAX Société Anonyme in the fourth quarter valued at $29,000. R Squared Ltd acquired a new stake in ABIVAX Société Anonyme in the 4th quarter valued at about $36,000. Bank of America Corp DE increased its holdings in ABIVAX Société Anonyme by 56.1% during the 4th quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock valued at $41,000 after acquiring an additional 1,990 shares in the last quarter. Ameriprise Financial Inc. acquired a new position in ABIVAX Société Anonyme during the fourth quarter worth about $85,000. Finally, Guggenheim Capital LLC purchased a new stake in shares of ABIVAX Société Anonyme in the fourth quarter valued at about $92,000. 47.91% of the stock is owned by institutional investors and hedge funds.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.